Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening

IF 4.7 Q1 VIROLOGY Tumour Virus Research Pub Date : 2023-06-01 DOI:10.1016/j.tvr.2023.200255
Louiza S. Velentzis , David Hawkes , Michael Caruana , Julia ML. Brotherton , Megan A. Smith , Lara Roeske , Khurram A. Karim , Suzanne M. Garland , C. David Wrede , Jeffery Tan , Cosette Wheeler , Philip E. Castle , Marion Saville , Karen Canfell
{"title":"Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening","authors":"Louiza S. Velentzis ,&nbsp;David Hawkes ,&nbsp;Michael Caruana ,&nbsp;Julia ML. Brotherton ,&nbsp;Megan A. Smith ,&nbsp;Lara Roeske ,&nbsp;Khurram A. Karim ,&nbsp;Suzanne M. Garland ,&nbsp;C. David Wrede ,&nbsp;Jeffery Tan ,&nbsp;Cosette Wheeler ,&nbsp;Philip E. Castle ,&nbsp;Marion Saville ,&nbsp;Karen Canfell","doi":"10.1016/j.tvr.2023.200255","DOIUrl":null,"url":null,"abstract":"<div><p>Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005–2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI:3.81–5.89) by LA; post-vaccination estimates were 1.67% (95%CI:1.21–2.13%) by LA, 1.49% (95%CI:1.05–1.93%) by cobas, and 1.63% (95%CI:1.17–2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI:13.79–17.60%) by LA; post-vaccination estimates were 9.06% (95%CI:8.02–10.09%) by LA, 8.47% (95%CI:7.47–9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV: 0.34 (95%CI:0.23–0.50), 0.68 (95%CI:0.55–0.84) and 0.58 (95%CI:0.48–0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/c2/main.PMC9925607.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumour Virus Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666679023000022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005–2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI:3.81–5.89) by LA; post-vaccination estimates were 1.67% (95%CI:1.21–2.13%) by LA, 1.49% (95%CI:1.05–1.93%) by cobas, and 1.63% (95%CI:1.17–2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI:13.79–17.60%) by LA; post-vaccination estimates were 9.06% (95%CI:8.02–10.09%) by LA, 8.47% (95%CI:7.47–9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV: 0.34 (95%CI:0.23–0.50), 0.68 (95%CI:0.55–0.84) and 0.58 (95%CI:0.48–0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
探索使用HPV初级筛查对HPV疫苗影响的人群监测策略
2017年12月,澳大利亚的宫颈筛查项目从细胞学转向HPV检测,并对HPV16/18进行基因分型。我们调查了计划数据是否可用于监测HPV疫苗接种计划(始于2007年)对HPV16/18流行率的影响,并将估计值与疫苗接种前的基准流行率进行了比较。疫苗接种前样本(2005-2008年)(n=1933;WHINURS),来自25至64岁女性,之前曾使用线性阵列(LA)进行过分析。通过cobas 4800(cobas)和LA对25至64岁女性的疫苗接种后样本(2013-2014)(n=2989;Compass试点)进行了历史可比性分析。LA的年龄标准化疫苗接种前HPV16/18患病率为4.85%(95%CI:3.81-5.89);LA的疫苗接种后估计值为1.67%(95%CI:1.21–2.13%),cobas的疫苗接种估计值为1.49%(95%CI:1.05–1.93%),cobas和LA检测非16/18 cobas阳性(cobas/LA)的疫苗接种预测值为1.63%(95%CI:1.17–2.08%)。LA的年龄标准化接种前致癌HPV患病率为15.70%(95%CI:13.79–17.60%);LA的疫苗接种后估计值为9.06%(95%CI:8.02–10.09%),cobas和cobas/LA的估计值为8.47%(95%CI:7.47–9.47%)。后与。HPV16/18、非16/18型HPV和致癌HPV的疫苗接种前率显著不同:分别为0.34(95%CI:0.23–0.50)、0.68(95%CI:0.55–0.84)和0.58(95%CI=0.48–0.69)。其他策略(所有cobas阳性的LA;所有样本的cobas和LA组合结果)具有相似的结果。如果持续应用单一方法,它将提供有关接种疫苗后HPV患病率相对变化的重要数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Tumour Virus Research
Tumour Virus Research Medicine-Infectious Diseases
CiteScore
6.50
自引率
2.30%
发文量
16
审稿时长
56 days
期刊最新文献
The imprint of viral oncoproteins on the variable clinical behavior among human papilloma virus-related oropharyngeal squamous cell carcinomas. Genomic diversity of HPV6 and HPV11 in recurrent respiratory papillomatosis: Association with malignant transformation in the lungs and clinical outcomes The SV40 virus enhancer functions as a somatic hypermutation-targeting element with potential tumorigenic activity Opportunities to advance cervical cancer prevention and care A new role for human papillomavirus 16 E2: Mitotic activation of the DNA damage response to promote viral genome segregation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1